Zhao Zichao, Liu Qilun, Wu Chunmei, Guo Wenjing, Li Jinping
Chifeng Cancer Hospital, Chifeng 024000, China.
General hospital of ningxia Medical University, Yinchuan 750004, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Apr 30;39(4):477-484. doi: 10.12122/j.issn.1673-4254.2019.04.15.
To study the expression of G9a in human breast cancer, its association with the clinicopathological characteristics of breast cancer, and its effect on the proliferation of breast cancer cells.
A total of 122 specimens of breast cancer tissues and 61 adjacent normal tissues resected between October, 2016 and October, 2017 were obtained from the Tissue Bank of Ningxia Medical University General Hospital. Immunohistochemistry and real-time PCR were used to detect the expression of G9a in the breast cancer tissues. The relationship of G9a with the clinicopathological features of the patients, molecular subtypes of breast cancer and the immunohistochemical markers was analyzed. A bioinformatics approach was used to analyze the expression of G9a in breast tissues and its association with the prognosis of the patients with breast cancer. UNC0631, a G9a inhibitor, was used to investigate the effect of G9a on the proliferation of breast cancer cells .
The results of immunohistochemical study, real-time PCR and bioinformatics analysis showed that G9a was highly expressed in human breast cancer tissues. G9a was highly expressed in breast invasive ductal carcinoma, and its expression was negatively correlated with age ( < 0.05). Her-2-overexpressing breast cancer showed high expressions of G9a, which was positively correlated with the expressions of Her-2, Ki-67 and E-cadherin ( < 0.05). Bioinformatics analysis suggested that a high G9a expression was an independent risk factor for poor prognosis of breast cancer. In cultured breast cancer cells, the application of the G9a inhibitor significantly inhibited the cell proliferation.
G9a is highly expressed in breast cancer tissues to promote the development and progression of breast cancer. A high G9a expression is an independent risk factor for poor prognosis of breast cancer, and G9a may serve as a new target for early diagnosis and treatment of breast cancer.
研究G9a在人乳腺癌中的表达、其与乳腺癌临床病理特征的关系及其对乳腺癌细胞增殖的影响。
收集宁夏医科大学总医院组织库2016年10月至2017年10月间切除的122例乳腺癌组织标本和61例癌旁正常组织标本。采用免疫组织化学和实时荧光定量PCR检测乳腺癌组织中G9a的表达。分析G9a与患者临床病理特征、乳腺癌分子亚型及免疫组化标志物的关系。采用生物信息学方法分析G9a在乳腺组织中的表达及其与乳腺癌患者预后的关系。使用G9a抑制剂UNC0631研究G9a对乳腺癌细胞增殖的影响。
免疫组织化学研究、实时荧光定量PCR和生物信息学分析结果显示，G9a在人乳腺癌组织中高表达。G9a在乳腺浸润性导管癌中高表达，其表达与年龄呈负相关（P<0.05）。人表皮生长因子受体2（Her-2）过表达的乳腺癌中G9a高表达，与Her-2、Ki-67和E-钙黏蛋白的表达呈正相关（P<0.05）。生物信息学分析提示，G9a高表达是乳腺癌预后不良的独立危险因素。在培养的乳腺癌细胞中，应用G9a抑制剂可显著抑制细胞增殖。
G9a在乳腺癌组织中高表达，促进乳腺癌的发生发展。G9a高表达是乳腺癌预后不良的独立危险因素，G9a可能成为乳腺癌早期诊断和治疗的新靶点。
